Literature DB >> 8952161

Do myelomatous plasma cells really express surface immunoglobulins?

M Ocqueteau1, J F San Miguel, M González, J Almeida, A Orfao.   

Abstract

Surface immunoglobulins (sIg) are traditionally considered to be absent in plasma cells (PC). However, it has recently been reported that up to one third of myeloma patients are positive for surface immunoglobulins. Nevertheless, this observation has not been confirmed in other studies. In order to assess whether or not sIg are really expressed by myelomatous PC and to exclude possible staining of either cytophilic or cytoplasmic Igs, simultaneous experiments were carried out with i) incubation at 37 degrees C, ii) blocking with non-conjugated anti-Ig light chains, and iii) cytoplasmic staining after cell membrane fixation and permeabilization. Triple staining for CD38/kappa/lambda was used in all cases and the staining intensity was quantitated in MESF (molecule equivalents of soluble fluorochrome). In addition, 20 B-CLL cases and 10 healthy donors were used as reference controls. Our study shows that 7 out the 20 patients (35%) analyzed expressed sIg and that the surface staining was specific.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8952161

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  6 in total

1.  Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma.

Authors:  Habil Zare; Ali Bashashati; Robert Kridel; Nima Aghaeepour; Gholamreza Haffari; Joseph M Connors; Randy D Gascoyne; Arvind Gupta; Ryan R Brinkman; Andrew P Weng
Journal:  Am J Clin Pathol       Date:  2012-01       Impact factor: 2.493

2.  Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain.

Authors:  Denise K Walters; Bonnie K Arendt; Renee C Tschumper; Xiaosheng Wu; Diane F Jelinek
Journal:  Exp Hematol       Date:  2017-10-13       Impact factor: 3.084

Review 3.  The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring "Multiple Myelomas".

Authors:  Antonio Giovanni Solimando; Matteo Claudio Da Vià; Niccolò Bolli; Torsten Steinbrunn
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

Review 4.  Radiotheranostic Agents in Hematological Malignancies.

Authors:  Jo Caers; Elodie Duray; Louise Vrancken; Guillaume Marcion; Valentina Bocuzzi; Kim De Veirman; Ahmet Krasniqi; Margaux Lejeune; Nadia Withofs; Nick Devoogdt; Mireille Dumoulin; Amelie Eriksson Karlström; Matthias D'Huyvetter
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

5.  Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.

Authors:  Katy J McCann; Rosemary Godeseth; Lindsey Chudley; Ann Mander; Gianfranco Di Genova; Paul Lloyd-Evans; Jonathan P Kerr; Vladimir B Malykh; Matthew W Jenner; Kim H Orchard; Freda K Stevenson; Christian H Ottensmeier
Journal:  Cancer Immunol Immunother       Date:  2015-05-16       Impact factor: 6.968

Review 6.  Adoptive T-cell therapy for Leukemia.

Authors:  Haven R Garber; Asma Mirza; Elizabeth A Mittendorf; Gheath Alatrash
Journal:  Mol Cell Ther       Date:  2014-08-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.